Abiomed Recent News
Piper Jaffray Raises PT On ABIOMED To $20
Wunderlich Securities Reiterates Buy and PT of $18 on Abiomed (ABMD)
Jefferies Reports NHIC Reversal Creates Positive Precedent For Abiomed
Jefferies Raises PT on Abiomed to $20
Jefferies Raises Abiomed Price Target To $18
Jefferies Raises PT On Abiomed To $18
Wunderlich Reports Growing Confidence In Abiomed's Project II Data
Piper Jaffray Maintains Overweight on ABIOMED (ABMD)
Rodman & Renshaw Downgrades Abiomed From MKT Perform To MKT Underperform
ABIOMED Announces Early Termination of Protect II (ABMD)